8-K
Relmada Therapeutics, Inc. (RLMD)
UNITEDSTATES
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM8-K
CURRENTREPORT
Pursuantto Section 13 or 15(d) of the
SecuritiesExchange Act of 1934
Date of Report (Date of earliest event reported): January 6, 2021
RELMADATHERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Nevada | 000-55347 | 45-5401931 |
|---|---|---|
| (State or other jurisdiction<br> <br><br> of incorporation) | (Commission File<br> Number) | (IRS Employer<br><br> Identification No.) |
| 880 Third Avenue, 12th Floor<br><br> <br>New York, NY | 10022 | |
| --- | --- | |
| (Address of principal<br> executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (646) 876-3459
| (Former name or former<br> address, if changed since last report) |
|---|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securitiesregistered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of exchange on which registered |
|---|---|---|
| Common<br> stock, $0.001 par value per share | RLMD | The<br> Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatorynote
Item 8.01.Other Events
The Company updated its corporate presentation, a copy of which is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
Item9.01. Financial Statements and Exhibits.
| (d) | Exhibits |
|---|---|
| Exhibit No. | Description |
| --- | --- |
| 99.1 | Corporate<br> Presentation, dated January 6, 2021 |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: January 6, 2021 | RELMADA THERAPEUTICS, INC. | |
|---|---|---|
| By: | /s/<br> Sergio Traversa | |
| Name: | Sergio Traversa | |
| Title: | Chief Executive<br> Officer |
2
Exhibit 99.1
